Clinical research progress in the treatment of BRAF V600 mutation-positive advanced melanoma

doi:10.19401/j.cnki.1007-3639.2022.05.010

Abstract

Abstract:

Most melanomas have BRAF V600E/K mutations, making V600 an important target for precision treatment of melanoma, and it can often be blocked by a combination of BRAF inhibitors and MEK inhibitors. The emergence of immune checkpoint inhibitors has also greatly improved the treatment outcome of patients with BRAF V600 mutation-positive advanced melanoma. Clinical trials are also underway to determine the best first-line treatment and the sequence of combination therapies for these patients. This paper reviewed the latest progress in the treatment of BRAF V600 mutation-positive advanced melanoma in the era of precision medicine.

Key words: BRAF V600 mutation, Advanced melanoma, Immune checkpoint inhibitors, BRAF inhibitors, MEK inhibitors

CLC Number:

R739.5

JIANG Jianyun, YING Hongmei. Clinical research progress in the treatment of BRAF V600 mutation-positive advanced melanoma[J]. China Oncology, 2022, 32(5): 445-450.

Figures/Tables 1

References 45

[1]	MICHIELIN O, VAN AKKOOI A C J, ASCIERTO P A, et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up^†[J]. Ann Oncol, 2019, 30(12): 1884-1901. doi: 10.1093/annonc/mdz411
[2]	RICHTIG G, HOELLER C, KASHOFER K, et al. Beyond the BRAF V600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients[J]. Br J Dermatol, 2017, 177(4): 936-944. doi: 10.1111/bjd.15436
[3]	HAUSCHILD A, ASCIERTO P A, SCHADENDORF D, et al. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: analysis from phase 2 and 3 clinical trials[J]. Eur J Cancer, 2020, 125: 114-120. doi: 10.1016/j.ejca.2019.10.033
[4]	ROBERT C, FLAHERTY K, NATHAN P, et al. Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600E/K-mutant advanced or metastatic melanoma[J]. Eur J Cancer, 2019, 109: 61-69. doi: 10.1016/j.ejca.2018.12.015
[5]	SIMEONE E, GRIMALDI A M, FESTINO L, et al. Combination treatment of patients with BRAF-mutant melanoma: a new standard of care[J]. BioDrugs, 2017, 31(1): 51-61. doi: 10.1007/s40259-016-0208-z
[6]	WOLCHOK J D, KLUGER H, CALLAHAN M K, et al. Nivolumab plus ipilimumab in advanced melanoma[J]. N Engl J Med, 2013, 369(2): 122-133. doi: 10.1056/NEJMoa1302369
[7]	LARKIN J, CHIARION-SILENI V, GONZALEZ R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma[J]. N Engl J Med, 2019, 381(16): 1535-1546. doi: 10.1056/NEJMoa1910836
[8]	WOLCHOK J D, CHIARION-SILENI V, GONZALEZ R, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma[J]. J Clin Oncol, 2022, 40(2): 127-137.
[9]	LUKE J J, FLAHERTY K T, RIBAS A, et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma[J]. Nat Rev Clin Oncol, 2017, 14(8): 463-482. doi: 10.1038/nrclinonc.2017.43
[10]	EGGERMONT A M M, BLANK C U, MANDALA M, et al. Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage Ⅲ melanoma: updated results from the EORTC 1325-MG/KEYNOTE-054 trial[J]. J Clin Oncol, 2020, 38(33): 3925-3936. doi: 10.1200/JCO.20.02110
[11]	LONG G V, HAUSCHILD A, SANTINAMI M, et al. Adjuvant dabrafenib plus trametinib in stage Ⅲ BRAF-mutated melanoma[J]. N Engl J Med, 2017, 377(19): 1813-1823. doi: 10.1056/NEJMoa1708539
[12]	ASCIERTO P A, DRÉNO B, LARKIN J, et al. 5-year outcomes with cobimetinib plus vemurafenib in BRAF V600 mutation-positive advanced melanoma: extended follow-up of the coBRIM study[J]. Clin Cancer Res, 2021, 27(19): 5225-5235. doi: 10.1158/1078-0432.CCR-21-0809
[13]	GUTZMER R, STROYAKOVSKIY D, GOGAS H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2020, 395(10240): 1835-1844. doi: 10.1016/S0140-6736(20)30934-X
[14]	ROBERT C, GROB J J, STROYAKOVSKIY D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma[J]. N Engl J Med, 2019, 381(7): 626-636. doi: 10.1056/NEJMoa1904059
[15]	DUMMER R, LONG G V, ROBERT C, et al. Randomized phase Ⅲ trial evaluating spartalizumab plus dabrafenib and trametinib for BRAF V600-mutant unresectable or metastatic melanoma[J]. J Clin Oncol, 2022, 40(13): 1428-1438. doi: 10.1200/JCO.21.01601
[16]	RIBAS A, DAUD A, PAVLICK A C, et al. Extended 5-year follow-up results of a phase Ⅰb study (BRIM7) of vemurafenib and cobimetinib in BRAF-mutant melanoma[J]. Clin Cancer Res, 2020, 26(1): 46-53. doi: 10.1158/1078-0432.CCR-18-4180
[17]	LONG G V, EROGLU Z, INFANTE J, et al. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib[J]. J Clin Oncol, 2018, 36(7): 667-673.
[18]	LARKIN J, HODI F S, WOLCHOK J D. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma[J]. N Engl J Med, 2015, 373(13): 1270-1271. doi: 10.1056/NEJMc1509660
[19]	WOLCHOK J D, CHIARION-SILENI V, GONZALEZ R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma[J]. N Engl J Med, 2017, 377(14): 1345-1356. doi: 10.1056/NEJMoa1709684
[20]	HODI F S, CHIARION-SILENI V, GONZALEZ R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial[J]. Lancet Oncol, 2018, 19(11): 1480-1492. doi: 10.1016/S1470-2045(18)30700-9
[21]	FREDERICK D T, PIRIS A, COGDILL A P, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma[J]. Clin Cancer Res, 2013, 19(5): 1225-1231. doi: 10.1158/1078-0432.CCR-12-1630
[22]	HU-LIESKOVAN S, MOK S, HOMET MORENO B, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF (V600E) melanoma[J]. Sci Transl Med, 2015, 7(279): 279ra41.
[23]	HU-LIESKOVAN S, ROBERT L, HOMET MORENO B, et al. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges[J]. J Clin Oncol, 2014, 32(21): 2248-2254. doi: 10.1200/JCO.2013.52.1377
[24]	RIBAS A, HODI F S, CALLAHAN M, et al. Hepatotoxicity with combination of vemurafenib and ipilimumab[J]. N Engl J Med, 2013, 368(14): 1365-1366. doi: 10.1056/NEJMc1302338
[25]	MINOR D R, PUZANOV I, CALLAHAN M K, et al. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab[J]. Pigment Cell Melanoma Res, 2015, 28(5): 611-612. doi: 10.1111/pcmr.12383
[26]	FERRUCCI P F, DI GIACOMO A M, DEL VECCHIO M, et al. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in -mutant melanoma[J]. Jr Immunother Cancer, 2020, 8(2): 66-68.
[27]	ASCIERTO P A, MANDALA M, FERRUCCI P F, et al. LBA40 SECOMBIT: The best sequential approach with combo immunotherapy[ipilimumab (I)/nivolumab (N)] and combo target therapy[encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: a phase Ⅱ randomized study[J]. Ann Oncol, 2021, 32: S1316-S1317. doi: 10.1016/j.annonc.2021.08.2118
[28]	ASCIERTO P A, MANDALA M, FERRUCCI P F, et al. LBA45 first report of efficacy and safety from the phase Ⅱ study SECOMBIT (SEquential COMBo immuno and targeted therapy study)[J]. Ann Oncol, 2020, 31: S1173-S1174.
[29]	JOSEPH R W, ELASSAISS-SCHAAP J, KEFFORD R, et al. Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab[J]. Clin Cancer Res, 2018, 24(20): 4960-4967. doi: 10.1158/1078-0432.CCR-17-2386
[30]	WARNER A B, POSTOW M A. Bigger is not always better: tumor size and prognosis in advanced melanoma[J]. Clin Cancer Res, 2018, 24(20): 4915-4917. doi: 10.1158/1078-0432.CCR-18-1311
[31]	DAUD A I, WOLCHOK J D, ROBERT C, et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma[J]. J Clin Oncol, 2016, 34(34): 4102-4109. doi: 10.1200/JCO.2016.67.2477
[32]	CARLINO M S, LONG G V, SCHADENDORF D, et al. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: a randomised clinical trial[J]. Eur J Cancer, 2018, 101: 236-243. doi: 10.1016/j.ejca.2018.06.034
[33]	CLEMENTE C G, MIHM M C Jr, BUFALINO R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma[J]. Cancer, 1996, 77(7): 1303-1310. doi: 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5
[34]	TRUJILLO J A, SWEIS R F, BAO R Y, et al. Tcell-inflamed versus non-T cell-inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection[J]. Cancer Immunol Res, 2018, 6(9): 990-1000. doi: 10.1158/2326-6066.CIR-18-0277
[35]	AYERS M, LUNCEFORD J, NEBOZHYN M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade[J]. J Clin Investig, 2017, 127(8): 2930-2940. doi: 10.1172/JCI91190
[36]	BAO R Y, STAPOR D, LUKE J J. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types[J]. Genome Med, 2020, 12(1): 90. doi: 10.1186/s13073-020-00787-6
[37]	NG S B, BIGHAM A W, BUCKINGHAM K J, et al. Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome[J]. Nat Genet, 2010, 42(9): 790-793. doi: 10.1038/ng.646
[38]	LI X, ZHANG Q, SHI Q Z, et al. Demethylase Kdm6a epigenetically promotes IL-6 and IFN-β production in macrophages[J]. J Autoimmun, 2017, 80: 85-94. doi: 10.1016/j.jaut.2017.02.007
[39]	CRISTESCU R, MOGG R, AYERS M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy[J]. Science, 2018, 362(6411): eaar3593. doi: 10.1126/science.aar3593
[40]	CHAKRABORTY A A, LAUKKA T, MYLLYKOSKI M, et al. Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate[J]. Science, 2019, 363(6432): 1217-1222. doi: 10.1126/science.aaw1026
[41]	WCULEK S K, CUETO F J, MUJAL A M, et al. Dendritic cells in cancer immunology and immunotherapy[J]. Nat Rev Immunol, 2020, 20(1): 7-24. doi: 10.1038/s41577-019-0210-z
[42]	WEISSMANN S, CLOOS P A, SIDOLI S, et al. The tumor suppressor CIC directly regulates MAPK pathway genes via histone deacetylation[J]. Cancer Res, 2018, 78(15): 4114-4125. doi: 10.1158/0008-5472.CAN-18-0342
[43]	LONG G V, GROB J J, NATHAN P, et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials[J]. Lancet Oncol, 2016, 17(12): 1743-1754. doi: 10.1016/S1470-2045(16)30578-2
[44]	ASCIERTO P A, ROBERT C, LEWIS K, et al. 1102P Clinical benefit in BRAF V600 mutation-positive melanoma defined by programmed death ligand 1 (PD-L1) and/or lactate dehydrogenase (LDH) status: exploratory analyses from the IMspire150 study[J]. Ann Oncol, 2020, 31: S745.
[45]	RUOCCO M R, AVAGLIANO A, GRANATO G, et al. Metabolic flexibility in melanoma: a potential therapeutic target[J]. Semin Cancer Biol, 2019, 59: 187-207. doi: 10.1016/j.semcancer.2019.07.016

NCT number	Follow-up time t/year	Number of cases n	Intervention/treatment	Primary outcome	Intervention/treatment
coBRIM (NCT01689519)^[12]	≥5.0	495	Vemurafenib/cobimetinib vs vemurafenib	Median PFS: 12.6 months vs 7.2 months; 5-year PFS rate: 14% vs 10%	2019.07.21
CheckMate-067 (NCT01844505)^[8]	≥5.0	945	Nivolumab/ipilimumab vs nivolumab vs ipilimumab	Median OS: NR vs 45.5 months vs 24.6 months; 5-year OS rate: 60% vs 46% vs 30%	2016.08.01
IMspire-150 (NCT02908672)^[13]	2.0	514	Vemurafenib/cobimetinib/atezolizumab vs vemurafenib/cobimetinib	Median PFS: 15.1 months vs 10.6 months	2019.10.11
KEYNOTE-22 (NCT01597908)^[14]	3.0	563	Dabrafenib/trametinib/pembrolizumab vs dabrafenib/trametinib	Median PFS: 16.9 months vs 10.7 months; Median OS: NR vs 26.3 months	2019.04.25
COMBI-I (NCT02967692)^[15]	2.3	532	Dabrafenib/trametinib/spartalizumab vs dabrafenib/trametinib	Median PFS: 16.2 months vs 12.0 months	2020.08.11